文献速递真菌感染细菌感染、耐药与抗菌药物

高危中性粒细胞减少患者接受氟康唑预防时经验性对比抢先抗真菌策略:欧洲癌症研究与治疗组织随机试验

Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
PubMed 文献 · Clin Infect Dis · 2023-01-01

该随机非劣效试验纳入急性髓系白血病、骨髓增生异常综合征及异基因造血细胞移植受者,在氟康唑400 mg每日预防基础上,比较经验性(A组)与抢先(B组)卡泊芬净策略。随机后42天总生存B组96.7%对比A组93.1%,B组不劣于A组;第84天侵袭性真菌病发生率B组7.7%对比A组6.6%,无显著差异;B组接受卡泊芬净的患者比例27%显著低于A组63%(P < .001)。

要点

  • 抢先抗真菌策略在高危中性粒细胞减少且氟康唑预防患者中安全。
  • 随机后42天总生存B组96.7%对比A组93.1%,B组不劣于A组。
  • 第84天侵袭性真菌病发生率B组7.7%对比A组6.6%,无显著差异;B组卡泊芬净使用27%对比A组63%(P < .001)。

核心结论

  • 对于接受氟康唑预防的高危中性粒细胞减少患者,抢先抗真菌策略是安全的,在不增加死亡或侵袭性真菌病的情况下使接受抗真菌治疗的患者数减半。

研究设计与样本

  • 欧洲癌症研究与治疗组织开展的随机非劣效试验,纳入急性髓系白血病或骨髓增生异常综合征患者及异基因造血细胞移植受者,随机分为经验性卡泊芬净组(A组)与抢先卡泊芬净组(B组),同时每日预防性使用氟康唑400 mg。
  • 共招募556例,549例符合条件:A组275例,B组274例;主要终点为随机后42天总生存。

主要发现

  • 80%的患者为需要大剂量化疗的急性髓系白血病或骨髓增生异常综合征,其中93%处于首次诱导阶段。
  • 随机后42天总生存B组96.7%(95%CI 93.8%-98.3%)对比A组93.1%(95%CI 89.3%-95.5%),B组不劣于A组。
  • 第84天侵袭性真菌病发生率B组7.7%(95%CI 4.5%-10.8%)对比A组6.6%(95%CI 3.6%-9.5%),无显著差异。
  • 接受卡泊芬净的患者比例B组27%显著低于A组63%(P < .001)。

临床怎么用

  • 原文结论为抢先抗真菌策略对接受氟康唑预防的高危中性粒细胞减少患者安全,使接受抗真菌治疗的患者数减半而未增加死亡或侵袭性真菌病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown. METHODS: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization. RESULTS: Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%-98.3%) when compared with arm A (93.1%; 95% CI, 89.3%-95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%-10.8%) in arm B vs 6.6% (95% CI, 3.6%-9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P < .001). CONCLUSIONS: The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Maertens J, Lodewyck T, Donnelly JP, et al. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. Clin Infect Dis. 2023. PMID: 35906831. doi:10.1093/cid/ciac623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。